Skip to main content
SpringerLink
Log in

Where Are the Nanodrugs? An Industry Perspective on Development of Drug Products Containing Nanomaterials

  • Commentary
  • Theme: Nanotechnology in Complex Drug Products: Learning from the Past, Preparing for the Future
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

While nanotechnology advancements have been applied to pharmaceutical products, the number of approved nanodrugs by global health authorities has not kept pace with research and development investments in the field. This article reviews the history of nanodrug development and provides an industrial context for realistic expectations in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

REFERENCES

  1. Wei A, Mehtala JG, Patri AK. Challenges and opportunities in the advancement of nanomedicines. J Control Release. 2012;164(2):236–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Langer R, Weissleder R. Nanotechnology. JAMA. 2015;313(2):135–6.

    Article  CAS  PubMed  Google Scholar 

  3. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. Nanomed Nanotechnol Biol Med. 2013;9(1):1–14.

    Article  CAS  Google Scholar 

  4. Chauhan VP, Jain RK. Strategies for advancing cancer nanomedicine. Nat Mater. 2013;12(11):958–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Juliano R. Nanomedicine: is the wave cresting? Nat Rev Drug Discov. 2013;12(3):171–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano. 2013;7(9):7442–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Venditto VJ, Szoka FC Jr. Cancer nanomedicines: so many papers and so few drugs! Adv Drug Deliv Rev. 2013;65(1):80–88.

  8. Alexander JW. History of the medical use of silver. Surg Infect. 2009;10(3):289–92.

    Article  Google Scholar 

  9. Feynman RP. There’s plenty of room at the bottom. Eng Sci. 1960;23(5):22–36.

  10. Kroto HW, Heath JR, O’Brien SC, Curl RF, Smalley RE. C 60: buckminsterfullerene. Nature. 1985;318(6042):162–3.

  11. Iijima S. Helical microtubules of graphitic carbon. Nature. 1991;354(6348):56–8.

    Article  CAS  Google Scholar 

  12. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol. 1964;8(5):660IN2–668IN10.

    Article  Google Scholar 

  13. Zerhouni E. The NIH, roadmap. Science. 2003;302(5642):63–72.

    Article  CAS  PubMed  Google Scholar 

  14. Barenholz YC. Doxil®–the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–34.

  15. Liversidge GG, Cundy KC, Bishop JF, Czekai DA, inventors; Sterling Drug Inc, assignee. Surface modified drug nanoparticles. United States patent US 5,145,684. 8 Sep 1992.

  16. Watson JD, Crick FH. Molecular structure of nucleic acids. Nature. 1953;171(4356):737–8.

    Article  CAS  PubMed  Google Scholar 

  17. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–7.

    Article  CAS  PubMed  Google Scholar 

  18. Finch G, Havel H, Analoui M, Barton RW, Diwan AR, Hennessy M, et al. Nanomedicine drug development: a scientific symposium entitled charting a roadmap to commercialization. AAPS J. 2014;16:1–7.

    Article  Google Scholar 

  19. Eaton MA, Levy L, Fontaine OM. Delivering nanomedicines to patients: a practical guide. Nanomed Nanotechnol Biol Med. 2015;11(4):983–92.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Phytoption LLC, West Lafayette, Indiana, USA

    Henry A. Havel

Authors
  1. Henry A. Havel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henry A. Havel.

Additional information

Guest Editors: Katherine Tyner, Sau (Larry) Lee, and Marc Wolfgang

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Havel, H.A. Where Are the Nanodrugs? An Industry Perspective on Development of Drug Products Containing Nanomaterials. AAPS J 18, 1351–1353 (2016). https://doi.org/10.1208/s12248-016-9970-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-016-9970-6

KEY WORDS

Search

Navigation